A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms FLASH
- Sponsors Chiesi Farmaceutici SpA
- 01 Aug 2018 Status changed from active, no longer recruiting to completed.
- 20 Apr 2018 Planned End Date changed from 30 Apr 2018 to 30 Jul 2018.
- 20 Apr 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Jul 2018.